Group items tagged

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes

The purpose of the NLA Junior Faculty Research is to encourage scholarly advancement of Junior Faculty in the pursuit of a career related to hyperlipidemia and other lipid disorders in humans. The NLA will fund eligible institutions to provide $70,000 per year in salary support for those actively involved in clinical and/or basic science that provides promise of developing new information in fields of study that could advance the diagnosis and management of lipid disorders such as biochemistry, physiology, or genetics as well as interventions that improve therapy. The institutions eligible shall be nonprofit and offer an environment that would logically support a young faculty member with appropriate equipment, space and experienced faculty for proposed studies. The proposal will identify a specific candidate with training and strong signs of early success in an appropriate area of research and with a plan for developing appropriate experiments or clinical studies. To be eligible, an applicant is expected to hold or be eligible for a doctoral level degree (PhD, PharmD or MD) prior to the date of the scheduled award. There must be a record of accomplishment in a relevant research area as manifest by publications or a PhD thesis of high quality. The application for the Basic Science Award may focus on any aspect of lipid metabolism that has relevance to human disease. This may include experiments at the laboratory bench involving structural chemistry, biochemistry, physiology or genetics.

This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

The LRP Impact Award mechanism is being offered for the first time in FY17. The LRP Impact Award encourages applications that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through inferential reasoning and/or critical review and analysis of the literature. Inclusion of preliminary data is encouraged. The following are important aspects of the Impact Award: * Impact: The proposed research should impact an area of paramount importance in lupus disease. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly describe the potential impacts of the proposed study on lupus and to convey its level of significance. * Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review. * Preliminary Data: Inclusion of preliminary data, such as unpublished data from the laboratory of the PI and/or data from published literature that are relevant to lupus and support the proposed research project, is encouraged, but not required. * Focus Areas: The proposed research must address at least one of the FY17 LRP Focus Areas. Clinical trials are not allowed under this Program Announcement.

In response to The Gabriella Miller Kids First Research Act ( https://www.congress.gov/bill/113th-congress/house-bill/2019/text), NIH, through the Common Fund, has established the Gabriella Miller Kids First Pediatric Research Program (Kids First). The Kids First program is expected to be a ten-year effort (2015 - 2024) that will build the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource). The Kids First Data Resource will be populated by genomic and phenotypic data and will be of high value to the pediatric research community by facilitating data mining across diverse conditions. During the first five years of this Program, data were generated and made publicly available following sequencing of DNA, and some RNA, samples from pediatric cancer and structural birth defects cohorts as outlined on the Kids First Common Fund website at https://commonfund.nih.gov/kidsfirst. In addition to increased understanding of individual pediatric conditions, a goal of establishing the Data Resource is to enable discovery of shared pathways whose disruption may lead to structural birth defects and/or susceptibility to childhood cancer. Therefore, representation of a wide variety of pediatric cancers and structural birth defects within the Data Resource is essential. The overall goal is to help researchers understand the underlying mechanisms of disease, leading to more refined diagnostic capabilities and ultimately more targeted therapies or interventions.

The AACR-The Mark Foundation for Cancer Research "Science of the Patient" (SOP) Grants Program represents a joint effort to stimulate novel research aimed at understanding the influence of the biology of the host (i.e., patient) on the genesis, development, treatment, and survivorship of cancer. Successful projects should emphasize the interplay of host physiological systems with the tumor and/or tumor microenvironment. Harnessing the powerful approach of examining cancer not as an isolated phenomenon but as a systemic disease that affects and is affected by both the normal and pathological functions of the patient's body, these grants are expected to yield important advancements in our understanding of cancer development, progression, and treatment. Individuals with innovative ideas that have the potential to affect future clinical practice are particularly encouraged to apply.  Each grant will provide $750,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies; equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; other research expenses; and indirect costs.

Each year, CLRA's Medical Advisory Committee, consisting of prominent internationally known and respected hematologists, reviews submitted research proposals from doctors nationwide. Using your contributions, we fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dread disease. The objectives of this committee are to direct the funds of the Association into the most promising projects, and where funding would not duplicate other funding sources. With your help, we are getting closer every day! Because of the support of friends like you, the scientific community is making incredible strides in developing chemotherapy regimens that are extending the lives of leukemia patients. Not everyone under treatment goes into remission but our research grants are funding the examinations into why this is so, and how we can continue to combat leukemia.